The arrival of amivantamab offers a significant step forward for patients battling cancers featuring c-MET overexpression. This unique antibody, a selective blocker of multiple MET kinase plus human epidermal growth https://lillinpir612760.wikipresses.com/7336363/amivantamab_a_promising_treatment_for_c_met_fueled_cancers